Aura Biosciences (NASDAQ:AURA) Price Target Raised to $24.00

Aura Biosciences (NASDAQ:AURA) had its price objective boosted by BTIG Research from $21.00 to $24.00 in a research report sent to investors on Friday morning, MarketBeat.com reports. They currently have a buy rating on the stock.

A number of other equities analysts have also issued reports on the company. HC Wainwright lifted their price target on Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday. JMP Securities boosted their price target on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Finally, Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Aura Biosciences currently has an average rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Trading Up 14.1 %

AURA opened at $11.74 on Friday. Aura Biosciences has a twelve month low of $5.99 and a twelve month high of $12.38. The firm has a market cap of $581.63 million, a price-to-earnings ratio of -6.31 and a beta of 0.37. The company has a fifty day simple moving average of $8.66 and a 200 day simple moving average of $8.07.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. On average, analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares in the company, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Los Pinos Elisabet De sold 24,992 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the completion of the transaction, the insider now directly owns 329,847 shares in the company, valued at $3,971,357.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the sale, the chief technology officer now directly owns 121,132 shares in the company, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Regency Capital Management Inc. DE raised its stake in shares of Aura Biosciences by 11.4% in the 1st quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock worth $6,163,000 after buying an additional 80,162 shares in the last quarter. American International Group Inc. raised its position in Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after acquiring an additional 3,782 shares in the last quarter. Levin Capital Strategies L.P. lifted its holdings in Aura Biosciences by 11.2% in the 1st quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock valued at $873,000 after acquiring an additional 11,200 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Aura Biosciences during the 1st quarter valued at about $144,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Aura Biosciences by 51.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after purchasing an additional 48,549 shares during the last quarter. 96.75% of the stock is owned by institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.